CoChat

Androgen receptor as potential therapeutic target in metastatic endometrial cancer

Open access
Tangen, Ingvild Løberg, Onyango, Therese Bredholt, Kopperud, Reidun, Berg, Anna, Halle, Mari K., Øyan, Anne M., Werner, Henrica M.J., Trovik, Jone, Kalland, Karl Henning, Salvesen, Helga B., Krakstad, Camilla · 2016 · Oncotarget
Cited by 68

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

// Ingvild Løberg Tangen 1, 2 , Therese Bredholt Onyango 1, 2 , Reidun Kopperud 1, 2 , Anna Berg 1, 2 , Mari K. Halle 1, 2 , Anne M. Øyan 3, 4 , Henrica M.J. Werner 1, 2 , Jone Trovik 1, 2 , Karl Henning Kalland 3, 4 , Helga B. Salvesen 1, 2, * , Camilla Krakstad 2, 5, * 1 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Norway 2 Department of Gynecology and Obstetrics, Haukeland University Hospital, Norway 3 Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Norway 4 Department of Microbiology, Haukeland University Hospital, Norway 5 Centre for Cancer Biomarkers, Department of Biomedicine, University of Bergen, Norway * These authors contributed equally to this work Correspondence to: Camilla Krakstad, email: camilla.krakstad@uib.no Keywords: androgen receptor, endometrial cancer, biomarker, survival Received: April 06, 2016 Accepted: June 13, 2016 Published: June 30, 2016 ABSTRACT Purpose: The expression and involvement of estrogen (ER) and progesterone receptor (PR) is extensively studied in endometrial cancer. Androgen receptor (AR) is a hormone receptor less studied in female cancers, and we here aim to investigate the expression level of AR in endometrial cancer precursor lesions, primary tumors and metastases, and its potential as therapeutic target. Results: Expression of AR was observed in 93% of hyperplasias, but only in 41% of non-endometrioid tumors. Compared to estrogen and progesterone receptor AR is more commonly expressed in metastatic lesions, and AR status is discordant in primary and metastatic lesions in a large proportion of cases. AR protein level was significantly associated with survival ( P < 0.001), and a calculated AR to ERα ratio identified a subgroup of patients with particular poor outcome. The anti-androgen enzalutamide may have a growth inhibitory effect in endometrial cancer cells based on experiments with primary endometrial tumor cells. Materials and Methods: 718 primary endometrial cancers and 298 metastatic lesions (from 142 patients) were investigated for expression of AR in relation to survival, clinical and histopathological data. Protein levels were investigated by immunohistochemistry and reverse phase protein array; mRNA levels by DNA oligonucleotide microarray. The effect of androgen stimulation and inhibition was tested on primary endometrial tumor cells. Conclusions: A large proportion of metastatic endometrial cancer lesions express AR, which may be a potential target in these patients. Treatment targeting AR may be of particular benefit in patients with high AR levels compared to ERα levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10334

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 68

Metadata

Authors
Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Øyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K. H., Salvesen, H. B., & Krakstad, C.
Venue
Oncotarget
Published
2016-06-30
Volume
7
Issue
31
Pages
49289-49298
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2465663488
Cited by
68
References
4
FWCI
9.90
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Androgen receptor as potential therapeutic target in metastatic endometrial cancer. https://app.cochat.ai/papers/10.18632/oncotarget.10334
The paper
Tangen, I. L., Onyango, T. B., Kopperud, R., Berg, A., Halle, M. K., Øyan, A. M., Werner, H. M. J., Trovik, J., Kalland, K. H., Salvesen, H. B., & Krakstad, C. (2016). Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget. https://doi.org/10.18632/oncotarget.10334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.